Zaouter Cédrick, Hemmerling Thomas M, Mion Stefano, Leroux Lionel, Remy Alain, Ouattara Alexandre
*Centre Hospitalier Universitaire (CHU) de Bordeaux, Service d'Anesthésie-Réanimation II, F-33000 Bordeaux, France; †Department of Anaesthesia, Division of Experimental Surgery, Arnold and Blema Steinberg Simulation Centre, McGill University, Montreal, Canada; ‡CHU de Bordeaux, Service de cardiologie, F-33000 Bordeaux, France; §University Bordeaux, Adaptation cardiovasculaire à l'ischémie, U1034, F-33600 Pessac, France; and ‖INSERM, Adaptation cardiovasculaire à l'ischémie, U1034, F-33600 Pessac, France.
Anesth Analg. 2017 Nov;125(5):1505-1512. doi: 10.1213/ANE.0000000000001737.
Recently, several trials have shown that closed-loop sedation is feasible. No study has used automated sedation in extremely frail patients, such as those scheduled for transcatheter aortic valve implantation (TAVI). We developed and tested a novel automated sedation system for this kind of population and surgery. The system integrates a decision support system that detects respiratory and hemodynamic events via smart alarms, which provide pertinent/related clinical suggestions and treatment options. The main objective was the feasibility of closed-loop sedation, defined as successful automated sedation without manual override. Secondary qualitative observations were clinical and controller performance.
Twenty patients scheduled for elective TAVI were enrolled. Sedation was administered via a closed-loop delivery system designed for propofol. The clinical performance of sedation was the efficacy to maintain a bispectral index (BIS) of 65. To evaluate the sedation performance, BIS values were stratified into 4 categories: excellent, very good, good, and inadequate sedation control, defined as BIS values within 10%, ranging from 11% to 20%, ranging from 21% to 30%, or >30% from the target value, respectively. The controller performance was calculated using Varvel parameters. Critical respiratory and hemodynamic events were documented. The former was defined as peripheral oxygen saturation <92% and/or respiratory rate <8/min, whereas the latter was considered a mean arterial pressure <60 mm Hg and/or heart rate <40 bpm.
Automated sedation was successful in 19 patients undergoing TAVI. One patient was excluded from the final analysis because of conversion to general anesthesia. The secondary observations revealed that the clinical performance allowed an excellent to good control during 69% (99% confidence interval, 53%-77%; interquartile range, 59%-79%) of the sedation time. Fifteen patients presented critical respiratory episodes, with a median of 3 events per hour of sedation. Six patients presented critical hemodynamic episodes, with a median of 2 events per hour of procedure.
The automated closed-loop sedation system tested could be used successfully for patients scheduled for a TAVI procedure. The results showed a satisfactory clinical performance of sedation control.
最近,多项试验表明闭环镇静是可行的。尚无研究在极度虚弱的患者中使用自动镇静,如计划进行经导管主动脉瓣植入术(TAVI)的患者。我们针对这类人群和手术开发并测试了一种新型自动镇静系统。该系统集成了一个决策支持系统,通过智能警报检测呼吸和血流动力学事件,这些警报提供相关的临床建议和治疗方案。主要目标是闭环镇静的可行性,定义为无需人工干预的成功自动镇静。次要的定性观察指标为临床和控制器性能。
纳入20例计划进行择期TAVI的患者。通过专为丙泊酚设计的闭环给药系统进行镇静。镇静的临床性能是维持脑电双频指数(BIS)为65的有效性。为评估镇静性能,将BIS值分为4类:优秀、非常好、良好和镇静控制不足,分别定义为BIS值在目标值的10%以内、11%至20%、21%至30%或>30%。使用Varvel参数计算控制器性能。记录关键的呼吸和血流动力学事件。前者定义为外周血氧饱和度<92%和/或呼吸频率<8次/分钟,而后者定义为平均动脉压<60 mmHg和/或心率<40次/分钟。
19例接受TAVI的患者自动镇静成功。1例患者因转为全身麻醉而被排除在最终分析之外。次要观察结果显示,在69%(99%置信区间,53%-77%;四分位间距,59%-79%)的镇静时间内,临床性能实现了优秀至良好的控制。15例患者出现关键呼吸事件,每小时镇静的事件中位数为3次。6例患者出现关键血流动力学事件,每小时手术的事件中位数为2次。
所测试的自动闭环镇静系统可成功用于计划进行TAVI手术的患者。结果显示镇静控制的临床性能令人满意。